# AMENDMENTS TO THE CLAIMS

## Listing of Claims:

This listing of claims will replace all prior versions and listings of the claims in the application.

1. (Currently Amended) A compound of formula (I), or a pharmaceutically acceptable salt thereof:

~~$R^1$-A-V-B-$R^2$~~

$R^1$-V-B-$R^2$

(I)

wherein V [[is]] represents a 5-membered heteroaryl ring ~~containing up to four heteroatoms selected from O, N and S, optionally substituted by $C_{1-4}$ alkyl~~of the formula:




wherein W is N and one of X and Y is N and the other is O;

~~A is -CH=CH- or $(CH_2)_n$;~~

B is -CH=CH- or $(CH_2)_n$, where one of the $CH_2$ groups may be replaced by O, $NR^5$, $S(O)_m$, C(O) or $C(O)NR^{12}$;

n is ~~independently 0, 1,~~ 2 or 3;

m is ~~independently~~ 0, 1 or 2;

$R^1$ is [[3- or ]]4-pyridyl~~, 4- or 5-pyrimidinyl or 2-pyrazinyl, any of which may be~~ optionally substituted by ~~one or more substituents selected from~~ 1 or 2 halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, $C_{3-7}$ cycloalkyl, aryl, $OR^6$, CN, $NO_2$, $S(O)_mR^6$, $CON(R^6)_2$, $N(R^6)_2$, $NR^{10}COR^6$, $NR^{10}SO_2R^6$, $SO_2N(R^6)_2$, [[a ]]4- to 7-membered heterocyclyl~~ group~~ or [[a ]]5- or 6-membered heteroaryl ~~group~~groups;

$R^2$ is 4- to 7-membered cycloalkyl substituted by $R^3$, $C(O)OR^3$, $C(O)R^3$ or $S(O)_2R^3$, or 4- to 7-membered heterocyclyl, containing one or two nitrogen atoms which is unsubstituted or substituted by $C(O)OR^4$, $C(O)R^3$, $S(O)_2R^3$, $C(O)NHR^4$, $P(O)(OR^{11})_2$ or a 5- or 6-membered nitrogen containing heteroaryl group;

$R^3$ is $C_{3-8}$ alkyl, $C_{3-8}$ alkenyl or $C_{3-8}$ alkynyl, any of which may be optionally substituted with up to 5 fluoro or chloro atoms, and may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $C_{1-4}$ alkyl$C_{3-7}$ cycloalkyl, $C_{1-4}$ alkylaryl, $C_{1-4}$ alkylheterocyclyl or $C_{1-4}$ alkylheteroaryl, any of which may be optionally substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^6$, CN, $CO_2C_{1-4}$ alkyl, $N(R^6)_2$ and $NO_2$;

$R^4$ is $C_{2-8}$ alkyl, $C_{2-8}$ alkenyl or $C_{2-8}$ alkynyl, any of which may be optionally substituted with up to 5 fluoro or chloro atoms, and may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $C_{1-4}$ alkyl$C_{3-7}$ cycloalkyl, $C_{1-4}$ alkylaryl, $C_{1-4}$ alkylheterocyclyl or $C_{1-4}$

alkylheteroaryl, any of which may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^6$, CN, $CO_2C_{1-4}$ alkyl, $N(R^6)_2$ and $NO_2$;

$R^5$ is hydrogen, $C(O)R^7$, $S(O)_2R^8$, $C_{3-7}$ cycloalkyl or $C_{1-4}$ alkyl optionally substituted by $OR^6$, $C_{3-7}$ cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein the cyclic groups may be substituted with one or more substituents selected from halo, $C_{1-2}$ alkyl, $C_{1-2}$ fluoroalkyl, $OR^6$, CN, $N(R^6)_2$ and $NO_2$;

$R^6$ are independently hydrogen $C_{1-4}$ alkyl, $C_{3-7}$ cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein the cyclic groups may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^9$, CN, $SO_2CH_3$, $N(R^{10})_2$ and $NO_2$; or a group $N(R^{10})_2$ may form a 4- to 7-membered heterocyclic ring optionally containing a further heteroatom selected from O and $NR^{10}$;

$R^7$ is hydrogen, $C_{1-4}$ alkyl, $OR^6$, $N(R^6)_2$, aryl or heteroaryl;

$R^8$ is $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, aryl or heteroaryl;

$R^9$ is hydrogen, $C_{1-2}$ alkyl or $C_{1-2}$ fluoroalkyl;

$R^{10}$ is hydrogen or $C_{1-4}$ alkyl;

$R^{11}$ is phenyl; and

$R^{12}$ is hydrogen, $C_{1-4}$ alkyl or $C_{3-7}$ cycloalkyl;

provided that the compound is not:

a) 4-(5-piperidin-4-yl-[1,2,4]oxadiazol-3-yl)pyridine;

b) 4-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)piperidine-1-carboxylic acid $^t$butyl ester; or

c) 4-[5-(4-butylcyclohexyl)-[1,2,4]oxadiazol-3-yl]pyridine[[;]]

~~d) 3-[5-(4-butylcyclohexyl)-[1,2,4]oxadiazol-3-yl]pyridine; or~~

~~e) 3-[5-(4-propylcyclohexyl)-[1,2,4]oxadiazol-3-yl]pyridine~~.

2-8. (Canceled)

9. (Currently Amended) A compound according to ~~claim 8~~claim 1, or a pharmaceutically acceptable salt thereof; wherein $R^1$ is 4-pyridyl optionally substituted by halo, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy or CN.

10. (Currently Amended) A compound according to ~~any one of the preceding claims~~claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^2$ is a 4- to 7-membered cycloalkyl substituted by $R^3$, or 4- to 7-membered heterocyclyl containing one nitrogen atom which is substituted by $C(O)OR^4$.

11. (Currently Amended) A compound according to ~~any one of the preceding claims~~claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^3$ is $C_{3-8}$ alkyl which may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl.

12. (Currently Amended) A compound according to ~~any one of the preceding claims~~claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is $C_{2-8}$ alkyl, $C_{2-8}$ alkenyl or $C_{2-8}$ alkynyl, any of which may be optionally substituted with up to 5 fluoro or chloro atoms, and may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl, aryl, 5- to 6-membered heteroaryl containing one or two

nitrogen atoms, $C_{1-4}$ alkyl$C_{3-7}$ cycloalkyl or $C_{1-4}$ alkylaryl, any of which may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^6$ and $CO_2C_{1-4}$ alkyl.

13. (Original) A compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein $R^4$ is $C_{3-6}$ alkyl optionally substituted with up to 5 fluoro or chloro atoms, and which may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl.

14. (Currently Amended) A compound according to ~~any one of the preceding claims~~claim 1, or a pharmaceutically acceptable salt thereof, wherein $R^5$ is $C_{1-4}$ alkyl.

15. (Currently Amended) A compound ~~of formula (I)~~ as defined in any one of Examples 1, ~~3 to 8~~3 to 5, 10 to 13, ~~16 to 50~~16 to 39, 41, 42,~~or~~ ~~52 to 149~~52 to 132, 134, 135, or 147 to 149, or a pharmaceutically acceptable salt thereof.

16. (Currently Amended) A compound according to claim 1~~having the formula (Id)~~, or a pharmaceutically acceptable salt thereof,~~:~~



~~(Id)~~

~~where two of W, X and Y are N, and the other is O;~~

~~A is –CH=CH– or $(CH_2)_n$;~~

wherein B is –CH=CH– or $(CH_2)_n$, where one of the $CH_2$ groups may be replaced by O, $NR^5$, $S(O)_m$ or C(O);

n is ~~independently 0, 1,~~ 2 or 3~~, provided that not both n are 0~~;

m is ~~independently~~ 0, 1 or 2;

~~$R^x$ and $R^y$ are independently selected from hydrogen, halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, $C_{3-7}$ cycloalkyl, aryl, $OR^6$, CN, $NO_2$, $S(O)_mR^6$, $CON(R^6)_2$, $N(R^6)_2$, $NR^{10}COR^6$, $NR^{10}SO_2R^6$, $SO_2N(R^6)_2$, a 4- to 7-membered heterocyclyl group and a 5- or 6-membered heteroaryl group;~~

$R^2$ is a 4- to 7-membered heterocyclyl containing one nitrogen atom which is substituted by $C(O)OR^4$~~Z is $C(O)OR^4$, $C(O)R^3$, $S(O)_2R^3$, $C(O)NHR^4$~~ or a ~~5- or~~ 6-membered nitrogen containing heteroaryl group;

~~$R^3$ is $C_{3-8}$ alkyl, $C_{3-8}$ alkenyl or $C_{3-8}$ alkynyl, any of which may be optionally substituted with up to 5 fluoro or chloro atoms, and may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $C_{1-4}$ alkyl$C_{3-7}$ cycloalkyl, $C_{1-4}$ alkylaryl, $C_{1-4}$ alkylheterocyclyl or $C_{1-4}$ alkylheteroaryl, any of which may be optionally substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^6$, CN, $CO_2C_{1-4}$ alkyl, $N(R^6)_2$ and $NO_2$;~~

$R^4$ is $C_{2-8}$ alkyl, $C_{2-8}$ alkenyl or $C_{2-8}$ alkynyl, any of which may be optionally substituted with up to 5 fluoro or chloro atoms, and may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $C_{1-4}$ alkyl$C_{3-7}$ cycloalkyl, $C_{1-4}$ alkylaryl, $C_{1-4}$ alkylheterocyclyl or $C_{1-4}$ alkylheteroaryl, any of which may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^6$, CN, $CO_2C_{1-4}$ alkyl, $N(R^6)_2$ and $NO_2$;

$R^5$ is hydrogen or $C_{1-4}$ alkyl;

$R^6$ are independently hydrogen, or $C_{1-4}$ alkyl, $C_{3-7}$ cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein the cyclic groups may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^9$, CN, $SO_2CH_3$, $N(R^{10})_2$ and $NO_2$; or a group $N(R^{10})_2$ may form a 4- to 7-membered heterocyclic ring optionally containing a further heteroatom selected from O and $NR^{10}$;

$R^9$ is hydrogen, $C_{1-2}$ alkyl or $C_{1-2}$ fluoroalkyl; and

$R^{10}$ is hydrogen or $C_{1-4}$ alkyl.

17. (Original) A compound according to claim 1 having the formula (Ie), or a pharmaceutically acceptable salt thereof:



(Ie)

wherein one of X and Y is N, and the other is O;

Q is O, $NR^5$ or $CH_2$;

R is hydrogen, halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, $C_{3-7}$ cycloalkyl, aryl, $OR^6$, CN, $NO_2$, $S(O)_mR^6$, $CON(R^6)_2$, $N(R^6)_2$, $NR^{10}COR^6$, $NR^{10}SO_2R^6$, $SO_2N(R^6)_2$, a 4- to 7-membered heterocyclyl group or a 5- or 6-membered heteroaryl group;

$R^4$ is $C_{2-8}$ alkyl, $C_{2-8}$ alkenyl or $C_{2-8}$ alkynyl, any of which may be optionally substituted with up to 5 fluoro or chloro atoms, and contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $C_{1-4}$ alkyl$C_{3-7}$ cycloalkyl, $C_{1-4}$ alkylaryl, $C_{1-4}$ alkylheterocyclyl or $C_{1-4}$ alkylheteroaryl, any of which may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^6$, CN, $CO_2C_{1-4}$ alkyl, $N(R^6)_2$ and $NO_2$;

$R^5$ is $C_{1-4}$ alkyl;

$R^6$ are independently hydrogen, or $C_{1-4}$ alkyl, $C_{3-7}$ cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein the cyclic groups may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^9$, CN, $SO_2CH_3$, $N(R^{10})_2$ and $NO_2$; or a group $N(R^{10})_2$ may form a 4- to 7-membered heterocyclic ring optionally containing a further heteroatom selected from O and $NR^{10}$;

$R^9$ is hydrogen, $C_{1-2}$ alkyl or $C_{1-2}$ fluoroalkyl;

$R^{10}$ is hydrogen or $C_{1-4}$ alkyl; and

p is 0 or 1.

18. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 17~~claim 1, including the ~~compounds~~compound of ~~provisos~~proviso c) ~~to e)~~, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

19. (Currently Amended) A method for the treatment of a disease or condition in which GPR116 plays a role comprising a step of administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 17~~claim 1, including the compounds of provisos ~~a) to e)~~a) to c), or a pharmaceutically acceptable salt thereof.

20. (Currently Amended) A method for the regulation of satiety comprising a step of administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 17~~claim 1, including the compounds of provisos ~~a) to e)~~a) to c), or a pharmaceutically acceptable salt thereof.

21. (Currently Amended) A method for the treatment of obesity comprising a step of administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 17~~claim 1, including the compounds of provisos ~~a) to e)~~a) to c), or a pharmaceutically acceptable salt thereof.

22. (Currently Amended) A method for the treatment of diabetes comprising a step of administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 17~~claim 1, including the compounds of provisos ~~a) to e)~~a) to c), or a pharmaceutically acceptable salt thereof.

23. (New) A method for the treatment of a disease or condition in which GPR116 plays a role comprising a step of administering to a subject in need thereof an effective amount of a compound of the formula:

$$R^1\text{-}V\text{-}B\text{-}R^2$$

or a pharmaceutically acceptable salt thereof;

wherein V represents a 5-membered heteroaryl ring of the formula:




wherein W is N and one of X and Y is N and the other is O;

B is -CH=CH- or $(CH_2)_n$, where one of the $CH_2$ groups may be replaced by O, $NR^5$, $S(O)_m$, C(O) or $C(O)NR^{12}$;

n is 0, 1, 2 or 3;

m is 0, 1 or 2;

$R^1$ is 3- or 4-pyridyl, 4- or 5-pyrimidinyl or 2-pyrazinyl, any of which may be optionally substituted by one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $C_{2-4}$ alkenyl, $C_{2-4}$ alkynyl, $C_{3-7}$ cycloalkyl, aryl, $OR^6$, CN, $NO_2$, $S(O)_mR^6$, $CON(R^6)_2$, $N(R^6)_2$, $NR^{10}COR^6$, $NR^{10}SO_2R^6$, $SO_2N(R^6)_2$, a 4- to 7-membered heterocyclyl group or a 5- or 6-membered heteroaryl group;

$R^2$ is 4- to 7-membered cycloalkyl substituted by $R^3$, $C(O)OR^3$, $C(O)R^3$ or $S(O)_2R^3$, or 4- to 7-membered heterocyclyl, containing one or two nitrogen atoms which is unsubstituted or substituted by $C(O)OR^4$, $C(O)R^3$, $S(O)_2R^3$, $C(O)NHR^4$, $P(O)(OR^{11})_2$ or a 5- or 6-membered nitrogen containing heteroaryl group;

$R^3$ is $C_{3-8}$ alkyl, $C_{3-8}$ alkenyl or $C_{3-8}$ alkynyl, any of which may be optionally substituted with up to 5 fluoro or chloro atoms, and may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $C_{1-4}$ alkyl$C_{3-7}$ cycloalkyl, $C_{1-4}$ alkylaryl, $C_{1-4}$ alkylheterocyclyl or $C_{1-4}$ alkylheteroaryl, any of which may be optionally substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^6$, CN, $CO_2C_{1-4}$ alkyl, $N(R^6)_2$ and $NO_2$;

$R^4$ is $C_{2-8}$ alkyl, $C_{2-8}$ alkenyl or $C_{2-8}$ alkynyl, any of which may be optionally substituted with up to 5 fluoro or chloro atoms, and may contain a $CH_2$ group that may be replaced by O, or $C_{3-7}$ cycloalkyl, aryl, heterocyclyl, heteroaryl, $C_{1-4}$ alkyl$C_{3-7}$ cycloalkyl, $C_{1-4}$ alkylaryl, $C_{1-4}$ alkylheterocyclyl or $C_{1-4}$ alkylheteroaryl, any of which may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^6$, CN, $CO_2C_{1-4}$ alkyl, $N(R^6)_2$ and $NO_2$;

$R^5$ is hydrogen, $C(O)R^7$, $S(O)_2R^8$, $C_{3-7}$ cycloalkyl or $C_{1-4}$ alkyl optionally substituted by $OR^6$, $C_{3-7}$ cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein the cyclic groups may be substituted with one or more substituents selected from halo, $C_{1-2}$ alkyl, $C_{1-2}$ fluoroalkyl, $OR^6$, CN, $N(R^6)_2$ and $NO_2$;

$R^6$ are independently hydrogen $C_{1-4}$ alkyl, $C_{3-7}$ cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein the cyclic groups may be substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, $OR^9$, CN, $SO_2CH_3$, $N(R^{10})_2$ and $NO_2$; or a group $N(R^{10})_2$ may form a 4- to 7-membered heterocyclic ring optionally containing a further heteroatom selected from O and $NR^{10}$;

$R^7$ is hydrogen, $C_{1-4}$ alkyl, $OR^6$, $N(R^6)_2$, aryl or heteroaryl;

$R^8$ is $C_{1-4}$ alkyl, $C_{1-4}$ fluoroalkyl, aryl or heteroaryl;

$R^9$ is hydrogen, $C_{1-2}$ alkyl or $C_{1-2}$ fluoroalkyl;

$R^{10}$ is hydrogen or $C_{1-4}$ alkyl;

$R^{11}$ is phenyl; and

$R^{12}$ is hydrogen, $C_{1-4}$ alkyl or $C_{3-7}$ cycloalkyl.